Suppr超能文献

ST段抬高型心肌梗死长期药物治疗依从性延迟教育提醒的整群随机对照试验(DERLA-STEMI)

Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI).

作者信息

Schwalm Jon-David, Ivers Noah M, Natarajan Madhu K, Taljaard Monica, Rao-Melacini Purnima, Witteman Holly O, Zwarenstein Merrick, Grimshaw Jeremy M

机构信息

Heart Investigation Unit, Hamilton General Hospital, Hamilton, ON, Canada; Population Health Research Unit, McMaster University, Hamilton, ON, Canada; Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada.

Family Practice Health Centre, Women's College Research Institute and Institute for Health Systems Solutions, Women's College Hospital, Toronto, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.

出版信息

Am Heart J. 2015 Nov;170(5):903-13. doi: 10.1016/j.ahj.2015.08.014. Epub 2015 Aug 20.

Abstract

BACKGROUND

Discontinuation of guideline-recommended cardiac medications post-ST-elevation myocardial infarction (STEMI) is common and associated with increased mortality. DERLA-STEMI tested an intervention to improve long-term adherence to cardiac medications post-STEMI.

METHODS AND RESULTS

Between September 2011 and December 2012, STEMI patients from one health region in Ontario, who underwent an angiogram during their admission and survived to discharge, were cluster randomized (by primary care provider) to intervention or control. The intervention was an automated system of personalized, educational-reminders sent to the patient and their family physician, urging long-term use of secondary-prevention medications. Interventions were mailed at 1, 2, 5, 8, and 11 months after discharge. A total of 852 eligible participants were randomized to intervention (n = 424, 287 clusters) and control (n = 428, 295 clusters); 87% completed a 12-month follow-up. The primary outcome, defined as the proportion of participants taking (persistence) all 4-cardiovascular medication classes (acetylsalicylic acid, angiotensin blockers, statin, and β-blocker) at 12 months, was 58.4% (intervention) and 58.9% (control; adjusted odds ratio 1.03, 95% CI 0.77-1.36). Medication adherence, as assessed by the Morisky Medication Adherence Score, was statistically significantly better in the intervention group as compared with control (65.3% vs 58.0%, adjusted odds ratio 1.35, 95% CI 1.01-1.81).

CONCLUSION

The results suggest suboptimal use of 4 of 4 cardiac medication classes at 12 months. There was no significant difference compared with usual care in the persistence to guideline-recommended medications post-STEMI when participants (and their family physicians) receive repeated postal reminders.

摘要

背景

ST段抬高型心肌梗死(STEMI)后停用指南推荐的心脏药物很常见,且与死亡率增加相关。DERLA-STEMI试验了一种干预措施,以提高STEMI后心脏药物的长期依从性。

方法与结果

2011年9月至2012年12月期间,安大略省一个健康区域的STEMI患者,在入院期间接受了血管造影并存活至出院,按初级保健提供者进行整群随机分组,分为干预组或对照组。干预措施是一个自动化系统,向患者及其家庭医生发送个性化的教育提醒,敦促长期使用二级预防药物。干预措施在出院后1、2、5、8和11个月邮寄。共有852名符合条件的参与者被随机分为干预组(n = 424,287个群组)和对照组(n = 428,295个群组);87%的人完成了12个月的随访。主要结局定义为在12个月时服用(持续服用)所有4种心血管药物类别(阿司匹林、血管紧张素阻滞剂、他汀类药物和β受体阻滞剂)的参与者比例,干预组为58.4%,对照组为58.9%(调整后的优势比为1.03,95%可信区间为0.77 - 1.36)。根据莫利斯基药物依从性评分评估,干预组的药物依从性在统计学上显著优于对照组(65.3%对58.0%,调整后的优势比为1.35,95%可信区间为1.01 - 1.81)。

结论

结果表明,在12个月时,4种心脏药物类别中的使用情况未达最佳。当参与者(及其家庭医生)收到重复的邮寄提醒时,STEMI后指南推荐药物的持续服用情况与常规护理相比无显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验